We address the entire spectrum of drug development. We use the cutting-edge computational biology technologies for novel drug candidate discovery. We also specialize in co-developing novel drug response biomarkers of the existing drug candidates, which allows improvement of likelihood of successful clinical trial, biomarker-driven indication expansion, and enhanced understanding of the drug's mechanism of action.